Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | 10% owner | October 31, 2023 | November 02, 2023 |
| LeonaBio, Inc.ATHA · Entity 1487 | Director · President & CEO | February 18, 2021 | February 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date October 31, 2023 · Filed November 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 4,391,432 |
Last balance in matching sequence
After 2023-10-31 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-10-31 · Purchase · Acquired 11,987 · Balance 4,379,087 F1: Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock. F2: Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest. Row 2 · 2023-10-31 · Purchase · Acquired 12,345 · Balance 4,391,432 F1: Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock. F2: Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock.
F2: Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.
LeonaBio, Inc.
Report date February 18, 2021 · Filed February 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2031-02-17 | Direct | 231,000 |
Reported balance
After 2021-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-18 · Grant · Acquired 231,000 · Balance 231,000 F1: One-fourth of the shares subject to the option will vest on January 8, 2022, and one-fourth of the shares subject to the option will vest on each year thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth of the shares subject to the option will vest on January 8, 2022, and one-fourth of the shares subject to the option will vest on each year thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2023 Filed Nov 2, 2023 21:14 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 12,345 | $0.26 | $3,228.22 |
DisclosureSEC source: 0001140361-23-051260 · form4.xml · nonDerivative · entry 2 KAWAS LEEN · CIK 0001822491 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 4,391,432 F1 · ownership.nature: Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock. F2 · ownership.nature: Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 21:14 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 11,987 | $0.26 | $3,146.59 |
DisclosureSEC source: 0001140361-23-051260 · form4.xml · nonDerivative · entry 1 KAWAS LEEN · CIK 0001822491 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 4,379,087 F1 · ownership.nature: Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock. F2 · ownership.nature: Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 22:33 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 231,000 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-21-012816 · doc4.xml · derivative · entry 1 KAWAS LEEN · CIK 0001822491 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,000 Underlying: Common Stock · 231,000 shares Expires 2031-02-17 F1 · derivative.exercise_date: One-fourth of the shares subject to the option will vest on January 8, 2022, and one-fourth of the shares subject to the option will vest on each year thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.